Search

Your search keyword '"LUNG diseases"' showing total 28,069 results
Start Over Descriptor "LUNG diseases" Topic business
28,069 results on '"LUNG diseases"'

1. PRO TIPS

Subjects
Volatile organic compounds, Lung diseases, Air fresheners, Business, Business, international
Abstract

Q: Can drinking hydrogen water really benefit my gut health? Yes! Research shows that a daily glass of hydrogen-enriched (or H2) water boosts antioxidant capacity and decreases inflammation, which protects [...]

Published
2024

2. LEGISLATIVE ROUNDUP: PA encourages vaccines as respiratory virus season begins

Subjects
Vaccination, Lung diseases, Influenza vaccines, Influenza, Business, General interest, Business, regional
Abstract

Byline: Bill O Boyle Sep. 29--WILKES-BARRE -- Leaders from the Pennsylvania Departments of Health and Insurance this week encouraged all Pennsylvanians to stay up to date on their annual vaccinations [...]

Published
2024

3. GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease | GSK

Subjects
Lung diseases, Industrial research -- United Kingdom, Research and development, Business, Business, international, University of Cambridge
Abstract

M2 PRESSWIRE-October 22, 2024-: GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease | GSK (C)1994-2024 M2 COMMUNICATIONS RDATE:21102024 * The Cambridge-GSK Translational Immunology Collaboration (CG-TIC) [...]

Published
2024

5. Phase II PREDICT-ILD Imaging Study Commences in Interstitial Lung Disease

Subjects
Medical research, Medicine, Experimental, Lung diseases, Imaging systems, Imaging technology, Business, News, opinion and commentary
Abstract

LONDON, Sept. 10, 2024 /PRNewswire/ -- Serac Healthcare Limited ('Serac Healthcare' or 'the Company'), a clinical radiopharmaceutical company developing innovative molecular imaging technologies, and the University of Exeter today announce [...]

Published
2024

6. Preventing Severe Respiratory Infections in Children

Author

Jonas, Lauren and Selbst, Steven M.

Subjects
Palivizumab, Lung diseases, Pediatrics, Infants, Infection, Business, Pharmaceuticals and cosmetics industries
Abstract

A refresher on best interventions for common respiratory disorders in children. This article originally appeared in the September issue of Contemporary Pediatrics and has been lightly edited. Most respiratory infections [...]

Published
2023

7. Investigators from Northwestern University Have Reported New Data on COVID-19 (Profibrotic Monocyte-derived Alveolar Macrophages Are Expanded In Patients With Persistent Respiratory Symptoms and Radiographic Abnormalities After Covid-19)

Subjects
United States. National Science Foundation, United States. National Institutes of Health, Lung diseases, Macrophages, Coronaviruses, College administrators, Business, Health, Health care industry
Abstract

2024 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Current study results on Coronavirus - COVID-19 have been published. [...]

Published
2024

8. Study Results from Hadassah-Hebrew University Broaden Understanding of Lung Diseases and Conditions (Detection of Antibody-drug Conjugate-induced Interstitial Lung Disease Using Circulating Cell-free Dna)

Subjects
Biopharmaceutics, Lung diseases, DNA, Genetic research, Methylation, Viral antibodies, Antibodies, Business, Health, Health care industry
Abstract

2024 OCT 22 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators discuss new findings in Respiratory Tract Diseases and Conditions - Lung Diseases and Conditions. [...]

Published
2024

11. Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update

Subjects
Insmed Inc. -- Company sales and earnings, Lung diseases, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Arikayce (Medication)
Abstract

-ARIKAYCE(amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023- -U.S. Launch Readiness for Brensocatib in [...]

Published
2024

12. Unmasking a Hidden Lung Threat: World NTM Day Calls for Awareness

Subjects
Lung diseases, Soil microbiology, International agencies, Business, News, opinion and commentary
Abstract

Nontuberculous Mycobacteria (NTM) Impacts Lives, But Early Diagnosis Offers Hope MIAMI, Aug. 1, 2024 /PRNewswire/ -- NTM Info & Research (NTMir), a pioneering global organization committed to addressing NonTuberculous Mycobacteria [...]

Published
2024

13. MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease

Subjects
Mannkind Corp., Executives, Lung diseases, Web sites, Pharmaceutical industry, Company Web site/Web page, Banking, finance and accounting industries, Business
Abstract

https://learnaboutntm.com/ provides information and resources for patients and caregivers Site launch in support of World NTM Awareness Day, August 4 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2024 (GLOBE [...]

Published
2024

14. FDA Grants Orphan Drug Designation (ODD) Status to Zymedi's ZMA001 for Pulmonary Arterial Hypertension

Subjects
United States. Food and Drug Administration, Lung diseases, Orphan drugs, Pulmonary hypertension, Business, News, opinion and commentary
Abstract

INCHEON, South Korea, July 30, 2024 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that its first-in-class antibody treatment ZMA001, currently in development for pulmonary arterial hypertension (PAH), has been designated [...]

Published
2024

16. Interstitial Lung Disease Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Subjects
Bayer AG -- Product development, Bristol-Myers Squibb Co. -- Product development, Boehringer Ingelheim GmbH -- Product development, Novartis AG -- Product development, AstraZeneca PLC -- Product development, Business -- Research, Lung diseases, Treprostinil -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 9, 2024-: Interstitial Lung Disease Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:09072024 Interstitial Lung [...]

Published
2024

17. Ventilators Market to be Worth $13.23 Billion by 2031 - Exclusive Report by Meticulous Research

Subjects
Lung diseases, Ventilators -- Market size, Business, News, opinion and commentary
Abstract

REDDING, Calif., June 20, 2024 /PRNewswire/ -- According to a new market research report, ' https://www.meticulousresearch.com/product/ventilators-market-5093?utm_source=PRnewswire&utm_medium=Paid&utm_campaign=Product&utm_content=20-06-2024 by Product (Instrument, Catheter, Mask, Tube) Mobility (Intensive Care, Portable) Interface (Invasive, Non-invasive) Age [...]

Published
2024

19. Eko Health Raises $41 Million to Scale AI-Driven Heart and Lung Disease Detection

Subjects
Lung diseases, Business, News, opinion and commentary
Abstract

Supporting more than 500,000 U.S. healthcare professionals, Eko combines FDA-cleared algorithms with digital medical devices to enhance the early detection of cardiac and pulmonary diseases during physical exams. SAN FRANCISCO, [...]

Published
2024

20. St. Baldrick's Foundation Kicks Off 'Cancer-Free Isn't Free' Campaign in Honor of June's Cancer Survivor Month

Subjects
Oncology, Experimental, Lung diseases, Cancer -- Research, Business, News, opinion and commentary
Abstract

LOS ANGELES, June 1, 2024 /PRNewswire/ -- In honor of National Cancer Survivor Month this June, the https://c212.net/c/link/?t=0&l=en&o=4180205-1&h=125969235&u=http%3A%2F%2Fwww.stbaldricks.org%2F&a=St.+Baldrick%27s+Foundation, the largest charity funder of childhood cancer research grants, is launching its [...]

Published
2024

21. Electric trucks get a boost from Biden, worrying trucking industry

Subjects
United States. Environmental Protection Agency, Nitrogen dioxide, Lung diseases, Global temperature changes, Air quality management, Diesel motor, Trucking, Air pollution, Business, Computers and office automation industries, Telecommunications industry
Abstract

Byline: Maxine Joselow Rayan Makarem worries about the air that his 2-year-old daughter breathes. More than 100 diesel-powered trucks rumble through their neighborhood every half an hour, spewing harmful pollutants [...]

Published
2024

23. Researcher at University of Cantabria Publishes Research in COVID-19 (Serological Biomarkers in Individuals with Interstitial Lung Disease after SARS-CoV-2 Infection and Association with Post-COVID-19 Symptoms)

Subjects
Medical research, Medicine, Experimental, Lung diseases, Infection, Disease susceptibility, Biological markers, Business, Health, Health care industry
Abstract

2024 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Fresh data on COVID-19 are presented in a new report. [...]

Published
2024

25. Data from Third Hospital of Shanxi Medical University Advance Knowledge in Chronic Obstructive Pulmonary Disease (COPD patients with high blood eosinophil counts exhibit a lower rate of omicron infection and milder post-infection symptoms)

Subjects
Lung diseases, Health care industry -- Exhibitions, Severe acute respiratory syndrome, Coronaviruses, Health care industry, Business, Health
Abstract

2024 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Investigators publish new report on chronic obstructive pulmonary disease. According [...]

Published
2024

26. Patent Issued for Treating inflammatory lung disease (USPTO 11993640)

Subjects
Lung diseases, Business, Government, Political science
Abstract

2024 JUN 20 (VerticalNews) -- By a News Reporter-Staff News Editor at Politics & Government Business -- According to news reporting originating from Alexandria, Virginia, by VerticalNews journalists, a patent [...]

Published
2024

28. Researcher from All India Institute of Medical Sciences (AIIMS) Reports on Findings in COVID-19 (Efficacy of lignocaine nebulization in patients with COVID-19 respiratory infection: An exploratory randomized double-blinded controlled trial)

Subjects
Lidocaine, Lung diseases, Coronaviruses, Business, Health, Health care industry
Abstract

2024 JUN 9 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- A new study on COVID-19 is now available. According to [...]

Published
2024

30. Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit

Subjects
Lung diseases, Homeopathy -- Materia medica and therapeutics, Respiratory agents, Therapeutics -- Innovations, Business, Business, international
Abstract

GALVESTON, Texas -- Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego. The Respiratory [...]

Published
2024

31. Voiant and Thirona announce commercial partnership for full scope services in imaging-based clinical trials for pulmonary diseases

Subjects
Lung diseases, Respiratory agents, Clinical trials, Cooperative agreement for product development, Business, News, opinion and commentary
Abstract

Voiant (USA) and Thirona (The Netherlands) are pleased to announce they have entered a global commercial partnership, combining Voiant's expertise in supporting clinical trials in pulmonary drug and treatment development [...]

Published
2024

32. Brayton Purcell, LLP featured in article published by The Hill

Subjects
Lung diseases, Alien labor, Silica, Business, News, opinion and commentary
Abstract

NOVATO, Calif., April 17, 2024 /PRNewswire/ -- On April 12, 2024, Brayton Purcell, LLP was referenced in news from an article published by The Hill, which highlights the alarming issue [...]

Published
2024

33. Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

Subjects
Insmed Inc., Societies, Lung diseases, Patient compliance, Treprostinil, Mediation, Associations, institutions, etc., Pharmaceutical industry, Business, News, opinion and commentary, Arikayce (Medication)
Abstract

-Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker- -Data to [...]

Published
2024

35. Reports Outline Chronic Obstructive Pulmonary Disease Findings from AstraZeneca [Short- and Long-term Impact of Prior Chronic Obstructive Pulmonary Disease Exacerbations On Healthcare Resource Utilization and Related Costs: an Observational...].

Subjects
CHRONIC obstructive pulmonary disease, LUNG diseases, REPORTERS & reporting, GENERAL practitioners, DISEASE exacerbation
Abstract

A study conducted by AstraZeneca in Gothenburg, Sweden, examined the impact of prior exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD) on healthcare resource utilization and related costs. The research found that patients with a history of exacerbations had higher healthcare resource utilization and costs compared to those without exacerbations. The study highlights the importance of managing and preventing exacerbations to optimize interventions and budgeting for related costs. [Extracted from the article]

Published
2024

36. Research from Hamad Medical Corporation Broadens Understanding of Ventilator-Associated Pneumonia (Noble element coatings on endotracheal tubes for ventilator-associated pneumonia prevention: A systematic review and meta-analysis of randomized...).

Subjects
RESPIRATORY diseases, VENTILATOR-associated pneumonia, RESPIRATORY infections, LUNG diseases, NOSOCOMIAL infections
Abstract

A new study conducted by researchers at Hamad Medical Corporation in Doha, Qatar, explores the use of noble element coatings on endotracheal tubes (ETTs) to prevent ventilator-associated pneumonia (VAP). The study found that noble metal-coated ETTs were effective in reducing the incidence of VAP compared to noncoated ETTs. However, there was no significant impact on mortality rates, duration of mechanical ventilation, or length of stay in the intensive care unit (ICU). The researchers recommend integrating these coated ETTs into a comprehensive care plan for emergency care settings. [Extracted from the article]

Published
2024

37. ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal(R) MRD Test.

Subjects
NON-small-cell lung carcinoma, CIRCULATING tumor DNA, LUNG tumors, LUNG cancer, LUNG diseases
Abstract

Personalis, Inc. presented findings at the European Society of Medical Oncology Congress (ESMO) Congress 2024 in Barcelona, Spain, regarding their NeXT Personal assay for detecting and monitoring residual and recurrent disease (MRD) in cancer patients. The assay detects small traces of circulating tumor DNA (ctDNA) in the blood and was shown to be effective in monitoring lung cancer patients and patients on immunotherapy. The studies presented at ESMO demonstrated strong detection rates for residual lung cancer, the ability to predict clinical outcomes, and the potential for stratifying patients for clinical outcome through dynamic monitoring with the NeXT Personal assay. [Extracted from the article]

Published
2024

38. Leukocyte telomere length and disease severity in cystic fibrosis.

Subjects
DIGESTIVE system diseases, RESPIRATORY diseases, CYSTIC fibrosis, PANCREATIC diseases, LUNG diseases
Abstract

A research paper published in Aging examined the relationship between leukocyte telomere length (LTL) and disease severity in cystic fibrosis (CF) patients. The study found that CF patients with more severe disease characteristics had shorter LTL, which may accelerate aging and increase susceptibility to age-related diseases. The researchers emphasized the importance of early CF diagnosis and timely therapeutic intervention to mitigate these effects. This study contributes to the growing body of research linking telomere shortening to chronic respiratory diseases. [Extracted from the article]

Published
2024

39. Data from AntiCancer Inc. Advance Knowledge in Xenografts (Non-invasive Direct Visualization of Luciferase-luciferin Emitted Light Producing True Images From an Orthotopic Lung Cancer Xenograft Model In Nude Mice Using an Ultra-sensitive...).

Subjects
FLUORESCENT proteins, LUNG tumors, LUNG cancer, LUNG diseases, COENZYMES
Abstract

A recent study conducted by AntiCancer Inc. in San Diego, California, has made advancements in the field of xenografts, specifically in the visualization of luciferase-luciferin emitted light in an orthotopic lung cancer xenograft model in nude mice. The researchers were able to directly visualize the low emitted light using a sensitive low-light camera and optics, which is a significant improvement over previous methods that relied on photon counting. The luciferase-luciferin signal was visible through the skin and produced true images, providing valuable insights for cancer research. This research has been peer-reviewed and can be accessed for further information. [Extracted from the article]

Published
2024

40. Data on Lung Diseases and Conditions Detailed by Researchers at Amrita Vishwa Vidyapeetham (Improving Early Detection and Classification of Lung Diseases With Innovative MobileNetV2 Framework).

Subjects
NOSOLOGY, LUNG diseases, RESEARCH personnel, RESPIRATORY diseases
Abstract

The article focuses on research from Amrita Vishwa Vidyapeetham aimed at enhancing early detection and classification of lung diseases. Topics include the development of two innovative models using MobileNetV2 and custom CNN architectures, their performance compared to existing methods, and the effectiveness of these models in improving diagnostic accuracy for lung conditions.

Published
2024

41. Investigators from AbbVie Inc. Zero in on Lung Cancer [Myc Family Amplification Dictates Sensitivity To Bet Bromodomain Protein Inhibitor Mivebresib (Abbv075) In Small-cell Lung Cancer].

Subjects
BIOTECHNOLOGY industries, PHARMACEUTICAL biotechnology industry, LUNG tumors, LUNG cancer, LUNG diseases
Abstract

A recent study conducted by AbbVie Inc. in North Chicago, Illinois, focused on small-cell lung cancer (SCLC), which accounts for approximately 15% of all lung cancers. The researchers found that SCLC cell lines with amplification of the MYC and MYCN genes were more sensitive to treatment with the pan-BET bromodomain protein inhibitor mivebresib (ABBV075). Silencing these genes partially reversed the antiproliferative effects of mivebresib. The study suggests that chromatin landscapes can determine cell states with unique gene expression programs, influencing sensitivity to epigenetic inhibitors like mivebresib. This research has been peer-reviewed and published in Molecular Cancer Research. [Extracted from the article]

Published
2024

42. Outcomes Insights Inc. Researchers Describe New Findings in Lung Cancer (Development of an algorithm to identify small cell lung cancer patients in claims databases).

Subjects
SMALL cell lung cancer, NON-small-cell lung carcinoma, LUNG cancer, LUNG tumors, LUNG diseases
Abstract

Researchers from Outcomes Insights Inc. have developed an algorithm to identify small cell lung cancer (SCLC) patients in claims databases. The current ICD-10 coding system cannot distinguish between SCLC and non-small cell lung cancer (NSCLC), so this algorithm is needed to characterize real-world SCLC patients. The algorithm, which is based on treatment data, showed good accuracy in identifying SCLC patients, with a sensitivity of 95% and specificity of 95%. This algorithm can help analyze treatment patterns, outcomes, healthcare resources, and costs for SCLC patients, improving the evidence-base for patient care. [Extracted from the article]

Published
2024

43. GSK plc Getting Ahead of Respiratory Diseases - Final

Subjects
Lung diseases, Business, Fasenra (Medication), Nucala (Medication)
Abstract

Presentation UNIDENTIFIED COMPANY REPRESENTATIVE: Hello, everyone. Welcome to our Getting ahead of Respiratory Diseases event with GSK management. As usual, the presentation was e-mailed to our distribution list earlier today [...]

Published
2023

44. TFF Pharmaceuticals enters CRADA with NIEHS for hyaluronan formulations

Subjects
United States. National Institute of Environmental Health Sciences, Hyaluronic acid, Lung diseases, Business, News, opinion and commentary
Abstract

TFF Pharmaceuticals has entered into a Collaborative Research and Development Agreement with the National Institute of Environmental Health Sciences to develop respirable, dry powder formulations of high molecular weight hyaluronan [...]

Published
2023

45. University Medical Devices Raises $1.6 Million in Seed Funding to Launch First-of-its-Kind Nasal Specimen Collection Device for Diagnosing Upper Respiratory Infections

Subjects
Medical equipment -- Marketing, Lung diseases, Medical centers, Infection, Physiological apparatus -- Marketing, Company marketing practices, Business, Business, international
Abstract

* MicroWash can deliver a more comfortable, faster and higher-quality sample than nasal swabs. * Device stands to set new gold standard for respiratory infection nasal sampling in post-pandemic world. [...]

Published
2024

46. Phoenix Children's Researcher Awarded $3 Million Grant to Develop New Therapy for Lung Diseases in Premature Babies

Subjects
Lung diseases, Drugs -- Vehicles, Infants (Newborn) -- Diseases, Drug delivery systems, Infants (Premature), Business, News, opinion and commentary
Abstract

PHOENIX, Feb. 13, 2024 /PRNewswire/ -- An internationally renowned research scientist at the https://bit.ly/3JqzkFn has been awarded a multimillion-dollar grant from the National Institutes of Health (NIH) to develop new [...]

Published
2024

47. AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

Subjects
Medical research, Medicine, Experimental, Communicable diseases, Lung diseases, Clinical trials, Business, Business, international
Abstract

-Enrolled patients allowed to continue on study- MENLO PARK, Calif. -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious [...]

Published
2024

48. Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Subjects
United States. Food and Drug Administration, Pipe lines, Lung diseases, Treprostinil, Pulmonary hypertension, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIA Confirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C., [...]

Published
2024

49. Data from Navi Mumbai Advance Knowledge in Respiratory Tract Diseases and Conditions (Approaches for Respiratory Sound Analysis in Identification of Respiratory Diseases)

Subjects
Medical research, Medicine, Experimental, Lung diseases, Biomedical engineering, Medical personnel, Business, Health
Abstract

2024 MAY 21 (NewsRx) -- By a News Reporter-Staff News Editor at Physician Business Week -- New research on respiratory tract diseases and conditions is the subject of a new [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results